

Invitation to presentation of BICO's preliminary Q2 performance 2022

On the occasion of the press release issued on Friday July 15 2022 regarding the preliminary performance for the second quarter, BICO invites to a combined presentation audiocast and telephone conference with the opportunity to ask questions. The conference will take place on Monday 18 July at 10:00 CET. President and CEO Erik Gatenholm, and Interim CFO Mikael Engblom will hold a short presentation, and thereafter be available to answer questions. The conference will be held in English.

The presentation audiocasts can be accessed via the following link:

<https://tv.streamfabriken.com/bico-press-conference-2022>

To participate via telephone, please call any of the following numbers (note that all numbers require pin code for access):

SE: +46850516386

UK: +442031984884

US: +14123176300

Pin code: 1820285#

Information presented in the audiocast will also be available on the company's website:

<https://bico.com/investors/>

Asa Contact Details

For further information, please contact:

Åsa Hillsten, SVP & Head of Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: ash@bico.com

About BICO

Founded in 2016, BICO (formerly CELLINK) is the world's leading bioconvergence company, with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people's health and lives. Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Attachments

[Invitation to presentation of BICO's preliminary Q2 performance 2022](#)